



Nanotechnologies for the Life Sciences

Edited by Challa Kumar

 WILEY-VCH

# Nanomaterials for Medical Diagnosis and Therapy



**NLS** 

## Contents

**Foreword** VII

**Preface** XXI

**List of Contributors** XXVII

<b>1</b>	<b>Nanotechnologies for Diagnosis – Present and Future</b>	<b>1</b>
	<i>Gareth A. Hughes</i>	
1.1	Introduction to Patient Diagnostics	1
1.2	Nanotechnology and Patient Diagnostics	2
1.3	Optical	9
1.3.1	Fluorescence	9
1.3.2	Quantum Dots	11
1.3.3	Surface Plasmon Resonance (SPR), Nanoparticles and Nanoshells	14
1.3.4	Fiber Optic Biosensors	19
1.4	Electrical	19
1.4.1	Nanomaterials for Enhanced Electron Transfer	20
1.4.2	Electrochemical Biosensors	24
1.5	Magnetic	28
1.6	Mechanical	30
1.7	Imaging Diagnostics	33
1.8	Nanotechnology-enhanced Tools	34
1.8.1	Analytical Tools	35
1.8.2	Raman Spectroscopy	35
1.8.3	Mass Spectrometry	36
1.8.4	Genetics	37
1.8.5	Immunoassays	39
1.9	Nanotechnology and the Future of Patient Diagnostics	40
1.9.1	Multifunctional Platforms	40
1.9.2	Real-time Monitoring	40
1.9.3	Multiplexed Diagnostic Assays	40
1.9.4	Point-of-care Diagnostics	41
1.9.5	Regulations, Risks and Ethics	42
	References	44

## 2 Superparamagnetic Nanoparticles of Iron Oxides for Magnetic Resonance Imaging Applications 51

*Jean-Marc Idee, Marc Port, Isabelle Raynal, Michel Schaefer, Bruno Bonnemain, Philippe Prigent, Philippe Robert, Caroline Robic, and Claire Corot*

- 2.1 Introduction 51
- 2.2 Physicochemical Characteristics 53
  - 2.2.1 Physicochemical Properties of the Crystal 54
  - 2.2.2 Hydrodynamic Particle Size and Charge 54
- 2.3 Pharmacology and Metabolism 56
  - 2.3.1 Role of Physicochemical Parameters 57
  - 2.3.2 Mechanism and Consequences of Interaction with Macrophages 58
  - 2.3.3 Pharmacokinetics 59
  - 2.3.4 Nanoparticle Vectorization 60
- 2.4 Current Clinical Uses and Future Developments 61
  - 2.4.1 Gastrointestinal Tract Imaging 61
  - 2.4.2 Liver and Spleen Diseases 63
  - 2.4.3 Lymph Node Metastases 64
  - 2.4.4 Blood Pool Characteristics 66
  - 2.4.5 Characterization of the Atheromatous Plaque 67
  - 2.4.6 Other Potential Uses 68
    - 2.4.6.1 Stroke 68
    - 2.4.6.2 Cerebral Tumor Characterization 68
    - 2.4.6.3 Multiple Sclerosis 69
    - 2.4.6.4 Arthritis 70
    - 2.4.6.5 Infection 70
    - 2.4.6.6 Kidney Imaging 71
    - 2.4.6.7 Acute Cardiac Transplant Rejection 72
    - 2.4.6.8 *In Vivo* Monitoring of Cell Therapy 72
    - 2.4.6.9 T-staging of Uterine Neoplasms 73
    - 2.4.6.10 MRI-detectable Embolotherapy 73
- 2.5 Conclusion 75
- References 76

## 3 Carbon Nanotube-based Vectors for Delivering Immunotherapeutics and Drugs 85

*Alberto Bianco, Wei Wu, Giorgia Pastorin, Cédric Klumpp, Lara Lacerda, Charalambos D. Partidos, Kostas Kostarelos, and Maurizio Prato*

- 3.1 Introduction 85
- 3.2 Chemical Functionalization of CNTs 86
  - 3.2.1 Noncovalent Functionalization 86
    - 3.2.1.1  $\pi$ - $\pi$  Stacking Interactions 86
    - 3.2.1.2 Hydrophobic Interactions 88
  - 3.2.2 Covalent Functionalization 89
    - 3.2.2.1 Defect Functionalization 90
    - 3.2.2.2 Sidewall Functionalization 91

3.3	CNTs in Diagnosis	96
3.3.1	CNTs in FETs	97
3.3.1.1	Fabrication	97
3.3.1.2	FET Biosensors	98
3.3.2	CNT-based Electrodes	100
3.3.2.1	Fabrication	101
3.3.2.2	Nanoelectrode Biosensors	102
3.4	CNT Cell Uptake	105
3.5	CNTs as Delivery Devices for Antigens and Adjuvants	107
3.5.1	Interaction of <i>f</i> -CNTs with CpG Motifs and Potentiation of their Immunostimulatory Activity	107
3.5.2	Presentation and Immunogenic Potential of Peptide Antigens Attached onto <i>f</i> -CNTs	109
3.6	CNTs for Drug Delivery	111
3.7	CNTs for Gene Transfer	115
3.7.1	Interaction with DNA and RNA	115
3.7.2	Delivery and Expression of Gene-encoding DNA and RNA	116
3.8	Health Impact of CNTs	118
3.8.1	Parameters of CNTs Related to Health Impact	119
3.8.1.1	Purity	119
3.8.1.2	Solvents	123
3.8.1.3	Surface of CNTs	123
3.8.1.4	Length	123
3.8.2	<i>In Vitro</i> Effect of CNTs	123
3.8.3	<i>In Vivo</i> Effects of CNTs	125
3.9	General Conclusions	127
	Acknowledgments	128
	References	128
<b>4</b>	<b>Core–Shell Nanoparticles for Drug Delivery and Molecular Imaging</b>	<b>143</b>
	<i>Sung Kyun Han, Ree Sun Kim, Jin Ho Lee, Giyoong Tae, Sun Hang Cho, and Soon Hong Yuk</i>	
4.1	Introduction	143
4.2	Core–shell Nanoparticles with a Lipid Core	145
4.3	Core–Shell Nanoparticles with a Polymeric Core	156
4.3.1	Hyaluronic Acid (HA)-functionalized PLGA Nanoparticles	157
4.3.2	Heparin-functionalized PLGA Nanoparticles	166
4.4	Core–shell Nanoparticles with a Metallic Core	174
4.5	Conclusions	181
	Acknowledgments	181
	References	182
<b>5</b>	<b>Nanotechnologies for Targeted Delivery of Drugs</b>	<b>189</b>
	<i>Pavel Brož and Patrick Hunziker</i>	
5.1	Introduction	189
5.2	Basic and Special Pharmacology	192

5.2.1	Outline	192
5.2.2	Basic Pharmacology	193
5.2.2.1	Absorption	193
5.2.2.2	Bioavailability	196
5.2.2.3	Distribution	197
5.2.2.4	Elimination	198
5.2.3	Special Pharmacology	201
5.2.3.1	Skin Epithelium	201
5.2.3.2	Mucosal Epithelium of the Respiratory Tract	202
5.2.3.3	Mucosal Epithelium of the Gastrointestinal Tract	202
5.2.3.4	Mononuclear Phagocyte System (MPS)	204
5.2.3.5	Endothelial Barrier	206
5.2.3.6	Cell Membrane	207
5.3	Strategies for Targeted Delivery – Observed in Nature	209
5.3.1	Outline	209
5.3.2	Bacteria	210
5.3.2.1	Host Invasion	210
5.3.2.2	Immune System Evasion	213
5.3.3	Viruses	215
5.3.3.1	Immune System Evasion	216
5.3.3.2	Host Cell Invasion	217
5.3.3.3	Viral Vectors for Therapeutic Applications	219
5.3.4	Prions	221
5.4	Strategies for Targeted Delivery – Designed by Man	223
5.4.1	Outline	223
5.4.2	Noninvasive Delivery Systems	223
5.4.2.1	Oral Delivery Systems	224
5.4.2.2	Transdermal Delivery Systems	224
5.4.2.3	Transmucosal Delivery Systems	225
5.4.3	Invasive Delivery Systems	225
5.4.4	Targeted Delivery to the Brain	226
5.4.5	Macrophage Targeting	228
5.4.6	Other Targets	230
5.5	Conclusion and Outlook	233
	References	234
<b>6</b>	<b>Nanoporous and Nanosize Materials for Drug Delivery Systems</b>	<b>255</b>
	<i>Yoshinobu Fukumori, Kanji Takada and Hirofumi Takeuchi</i>	
6.1	Introduction	255
6.2	Nanomaterials for Coating	256
6.2.1	Commercially Available Aqueous Polymeric Nanomaterials	257
6.2.2	Novel Terpolymer Nanoparticles for Coating	259
6.2.3	Core-shell Nanoparticles for Fine Particle Coating	260
6.2.4	Core-Shell Nanoparticles for Thermosensitively Drug-releasing Microcapsules	261

6.2.5	Chitosan Nanoparticles for Microparticle Coating	263
6.3	Materials for Nanoparticulate Therapy and Diagnosis	264
6.3.1	Inorganic Nanoparticles	265
6.3.2	Polymeric Nanoparticles	267
6.3.3	Other Case Studies	267
6.4	Nanoporous Materials as Drug Delivery System Carriers	270
6.4.1	Inorganic Calcium Compounds	270
6.4.2	Silastic Compounds	271
6.4.2.1	Nanoporous Silastic Materials for Solidifying Oily Drugs	271
6.4.2.2	Nanoporous Silastic Materials for Poorly Absorbable Drugs	275
6.4.2.3	Nanoporous Silica Materials for Controlled Release of Drugs	278
6.4.3	Carbon Nanotubes (CNTs)	280
6.4.3.1	CNTs for Oral Delivery of Protein Drug	280
6.4.3.2	CNTs for Intracellular Delivery of Protein	282
6.4.3.3	Toxicity of CNTs	284
6.4.3.4	Functionalized CNTs ( <i>f</i> -CNTs) for Drug Delivery	285
6.4.3.5	<i>f</i> -CNTs for Gene Delivery	286
6.4.4	CNHs for Drug Delivery	286
6.5	Physicochemical Aspects of Porous Silastic Materials for Drug Delivery	287
6.5.1	Solid Dispersion Particles with Porous Silica	288
6.5.2	Mesoporous Silica	295
	References	299
<b>7</b>	<b>NANOEGG® Technology for Drug Delivery</b>	<b>310</b>
	<i>Yoko Yamaguchi and Rie Igarashi</i>	
7.1	Introduction	310
7.2	New Nanoparticles with a Core–Shell Structure: The NANOEGG System	311
7.2.1	Physicochemical Properties and Action of ATRA	311
7.2.2	NANOEGG Preparation and Characterization	314
7.2.3	Improved Lability of ATRA in the NANOEGG System	317
7.3	NANOEGG for Dermatological Aspects	319
7.3.1	Improved Irritation of ATRA in the NANOEGG System	320
7.3.2	Pharmacological Effects of the NANOEGG System	323
7.3.3	Expression of mRNA Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) on Mouse Skin	325
7.3.4	Proliferation and Differentiation of Keratinocytes	326
7.3.5	Production of Hyaluronic Acid (HA) in the Epidermal Layer	328
7.3.6	Hyperpigmentation and Fine Wrinkle Improvements by NANOEGG Treatment on Animal Skin	330
7.3.7	Clinical Trials of Fine Wrinkles and Brown Spots on the Human Face	331
7.4	Why does NANOEGG Show the High Performance on the Improvement of Brown Spot and Wrinkles?	334

7.5	NANOEGG for Other Indications	335
7.6	NANOEGG for Other Drugs	338
7.7	Conclusion	338
	References	339
<b>8</b>	<b>Polymeric Nanomaterials – Synthesis, Functionalization and Applications in Diagnosis and Therapy</b>	<b>342</b>
	<i>Jutta Rieger, Christine Jérôme, Robert Jérôme, and Rachel Auzély-Velty</i>	
8.1	Introduction	342
8.2	Polymer Materials Used for the Synthesis of Nanoparticles	345
8.2.1	Natural Polymers	346
8.2.2	Degradable Synthetic Polymers	349
8.2.3	Nondegradable Synthetic Polymers	352
8.2.4	PEO	352
8.3	Preparation of Polymeric Nanoparticles	354
8.3.1	Preparation of Nanospheres from Preformed Polymers	354
8.3.1.1	Emulsion-evaporation	354
8.3.1.2	Salting-out	355
8.3.1.3	Emulsification-diffusion	356
8.3.1.4	Nanoprecipitation	356
8.3.2	Synthesis of Nanospheres by <i>In Situ</i> Polymerization	357
8.3.3	Preparation of Nanocapsules	358
8.4	Surface Functionalization	359
8.4.1	Functionalization with Biological (Macro)molecules	359
8.4.2	Functionalization with Specific Ligands: Specific Interaction through Biological Recognition	360
8.4.2.1	Mono- or Oligosaccharides (Carbohydrates)	360
8.4.2.2	Folate Receptor	361
8.4.2.3	Antibodies	362
8.4.2.4	Biotin	362
8.4.3	Strategies for Surface Modification	363
8.4.3.1	Adsorption on Preformed Nanoparticles	364
8.4.3.2	Functional Surfactants as Stabilizers and Surface Modifiers	366
8.4.3.3	Emulsion, Miniemulsion or Dispersion Polymerization	369
8.4.3.4	Covalent Linking of Functional Molecules to Preformed Nanoparticles	370
8.4.4	Analytical Techniques for Surface Modification	375
8.4.4.1	Physicochemical Techniques	376
8.4.4.2	Biological Assays/Methods	377
8.5	Applications	380
8.5.1	Drug Delivery Systems	380
8.5.1.1	Routes of Administration	380
8.5.1.2	Therapeutic Applications of Nanoparticles	382
8.5.1.3	Triggered Release	384

- 8.5.2 Diagnosis 388
  - 8.5.2.1 Fluorescence Labeling of Polymeric Nanoparticles 388
  - 8.5.2.2 Contrast Agents for MRI 392
  - 8.5.2.3 Magnetic Nanoparticles for *In Vitro* Assays 393
  - 8.5.2.4 Electron Dense Agents for Transmission Electron Microscopy (TEM) 396
  - 8.5.2.5 Radiolabeled Nanoparticles 396
- 8.6 Conclusion and Perspectives 396
- References 397

## **9 Polymeric Nanoparticles for Drug Delivery 409**

*Paraskevi Kallinteri and Martin C. Garnett*

- 9.1 Introduction: Application of Nanoparticles for Noncancer Applications 409
  - 9.1.1 Physiological and Uptake of Particles 410
    - 9.1.1.1 Routes of Tissue and Cellular Uptake of Particles 410
    - 9.1.1.2 Uptake by Macrophages and Lymphoid Tissues 411
    - 9.1.1.3 Mucosal-associated Lymphoid Tissues (MALT) 411
  - 9.1.2 Routes of Delivery 412
    - 9.1.2.1 Oral 412
    - 9.1.2.2 Nasal 413
    - 9.1.2.3 Pulmonary 413
    - 9.1.2.4 Transdermal/Subcutaneous 414
- 9.2 Drug Delivery 415
  - 9.2.1 Ocular Delivery 415
    - 9.2.1.1 Anatomy of the Eye 415
    - 9.2.1.2 Pathology 416
    - 9.2.1.3 Drug Delivery 416
    - 9.2.1.4 Tolerability 422
    - 9.2.1.5 Future Prospects for Nanoparticles in Ocular Delivery 422
  - 9.2.2 Macrophage-related Diseases 423
    - 9.2.2.1 Leishmaniasis 423
    - 9.2.2.2 Other Parasitic Infections 426
  - 9.2.3 Antifungal 427
    - 9.2.3.1 Treatment 427
    - 9.2.3.2 Drug Delivery Systems 428
  - 9.2.4 Tuberculosis 431
    - 9.2.4.1 Physiology and Pathology 431
    - 9.2.4.2 Treatment 431
    - 9.2.4.3 Future Prospects 434
  - 9.2.5 AIDS 434
    - 9.2.5.1 Pathology 434
    - 9.2.5.2 Treatment 434
    - 9.2.5.3 Nanoparticle Delivery Systems 435
    - 9.2.5.4 Vaccines and AIDS 439



9.2.6	Vaccines	441
9.2.6.1	Delivery Route	442
9.2.7	Diabetes	451
9.2.7.1	Treatment	451
9.2.7.2	Delivery Routes	452
9.3	Conclusions	460
	References	461
<b>10</b>	<b>Solid Lipid and Polymeric Nanoparticles for Drug Delivery</b>	<b>471</b>
	<i>José Luis Pedraz, Gorka Orive, Manoli Igartua, Alicia R. Gascón, Rosa M. Hernández, Maria Angeles Solinis, and Amaia Esquisabel</i>	
10.1	Introduction	471
10.2	SLNs	472
10.2.1	Introduction	472
10.2.2	Composition	473
10.2.3	Production Processes	474
10.2.3.1	Preparation Techniques	474
10.2.3.2	Scaling-up, Sterilization and Drying	475
10.2.4	Drug Incorporation, Loading, Incorporation Efficiency, Nanoparticle Recovery and Drug Release	476
10.2.4.1	Drug Incorporation	476
10.2.4.2	Drug Loading	477
10.2.4.3	Determination of Nanoparticle Recovery and Drug Incorporation Efficiency	477
10.2.4.4	Drug Release	478
10.2.5	Related Structures and Stability	478
10.2.6	Analytical Characterization of SLNs	480
10.2.6.1	Particle Size	480
10.2.6.2	The $\zeta$ Potential	481
10.2.6.3	Crystallinity and Polymorphism and Colloidal Structures	481
10.2.7	Applications	481
10.2.7.1	Gene Therapy	482
10.2.7.2	Peptide and Protein Delivery	486
10.2.7.3	Low-soluble Drugs	488
10.2.7.4	Topical and Transdermal Administration	490
10.2.7.5	Cosmetic Applications for SLNs	491
10.3	Polymeric Nanoparticles	491
10.3.1	Introduction	491
10.3.2	Nanoparticle Preparation Methods	492
10.3.2.1	Nanoparticles Prepared by <i>In Situ</i> Polymerization of Monomers	492
10.3.2.2	Nanoparticles Prepared from Preformed Polymers	493
10.3.3	Characterization of Polymeric Nanoparticles	494
10.3.4	Pharmaceutical Applications of Nanoparticles	495
10.3.4.1	Protein Delivery	495

10.3.4.2	Protein Delivery by Mucosal Routes	496
10.3.4.3	Vaccine Adjuvants	498
	References	499
<b>11</b>	<b>Intelligent Hydrogels in Nanoscale Sensing and Drug Delivery Applications</b>	<b>509</b>
	<i>J. Zach Hilt</i>	
11.1	Introduction	509
11.2	Intelligent Hydrogels	510
11.2.1	Ionic Hydrogels	510
11.2.2	Temperature-responsive Hydrogels	510
11.2.3	Biohybrid Hydrogels	510
11.2.4	Imprinted Hydrogels	511
11.3	Sensor Applications	511
11.3.1	Actuation Detection	511
11.3.2	Optical Detection	513
11.3.3	Electrical Detection	517
11.4	Drug Delivery Applications	519
11.4.1	Micro/nanoscale Devices	520
11.4.2	Nanoscale Macromolecular Structures	520
11.5	Conclusions	522
	References	522
<b>12</b>	<b>Nanoshells for Drug Delivery</b>	<b>527</b>
	<i>Melgardt M. De Villiers and Yuri Lvov</i>	
12.1	Introduction	527
12.2	Metallic Nanoshells	528
12.2.1	Synthesis of the Nanoshells	528
12.2.2	Application in Nanomedicine	530
12.3	Nanoshells Formed by Polyion E-LbL Self-assembly	532
12.3.1	Preparation of E-LbL Nanoshells	532
12.3.1.1	Proving the Nanoshells	535
12.3.1.2	Influence of the Core on Nanoshell Properties	538
12.3.1.3	Barrier Properties of E-LbL Assembled Nanoshells	539
12.3.2	Controlled Release of Active Pharmaceutical Ingredients Encapsulated by E-LbL Assembled Nanoshells	540
12.3.2.1	Nanoshell Permeability for Low-molecular-weight Compounds	542
12.3.2.2	Nanoshell Permeability for High-molecular-weight Compounds	543
12.3.3	E-LbL Assembled Nanoshells as Protective and Functional Barriers	545
12.3.4	Magnetic Nanoshells	548
12.3.5	Nano-organized Shells with Functions other than a Adjustable Diffusion Barrier	550
12.3.5.1	Colloidal Stabilization	550
12.3.5.2	Interpolyelectrolyte Complex Formation	550

12.3.5.3	Biomimetic Approach	551
12.4	Conclusion	552
	References	553
<b>13</b>	<b>Bionanoparticles and their Biomedical Applications</b>	<b>557</b>
	<i>L. Andrew Lee, Hannah N. Barnhill, and Qian Wang</i>	
13.1	Introduction	557
13.2	BNPs	558
13.3	Genetic and Chemical Alterations of BNPs	560
13.3.1	Chemical Modifications	560
13.3.1.1	Conventional Bioconjugation Methods for Selective Modifications	560
13.3.1.2	“Click Chemistry” for Bioconjugation of BNPs	567
13.3.1.3	New Developments in Tyrosine Modification	569
13.3.2	Genetic Alterations	570
13.3.2.1	Heterologous Peptide Insertions	571
13.3.2.2	NAA Substitutions	576
13.3.2.3	Protein Expression Systems	576
13.4	BNPs in Therapeutics	577
13.4.1	Cell Targeting	578
13.4.2	Gene Delivery	579
13.4.3	Bioimaging	580
13.4.4	Drug Encapsulation and Release	583
13.5	Immune Response	584
13.5.1	Vaccine Development	584
13.5.2	Immune Modulation	585
13.6	Future Directions	586
	Acknowledgments	587
	References	587
<b>14</b>	<b>Nanotechnology for Gene Therapy – HVJ-E Vector</b>	<b>597</b>
	<i>Hironori Nakagami, Yasuhiko Tabata, and Yasufumi Kaneda</i>	
14.1	Introduction	597
14.2	Biological Barriers to Gene Transfer	599
14.2.1	Reaching Target Cells	599
14.2.1.1	Recognition by Specific Target Tissues	599
14.2.1.2	Avoidance of Nonspecific Uptake	599
14.2.1.3	Resistance to Degradation in Systemic Circulation	600
14.2.2	Crossing the Cell Membrane	600
14.2.3	Nuclear Targeting	601
14.2.4	Regulation of Gene Expression	602
14.2.4.1	Stable Retention of Transgenes	602
14.2.4.2	Regulation of Transcription	603
14.3	HVJ-E Vector	604
14.3.1	Development of HVJ-E Vector	604
14.3.2	Approaches to Cancer Gene Therapy Utilizing HVJ-E Vector	609

- 14.3.2.1 Transfection of Dendritic Cells (DCs) with Melanoma-associated Antigen (MAA) using HVJ Envelope Vector for Immunotherapy of Melanoma 609
- 14.3.2.2 Fusion of DC Tumor Cells and Simultaneous Gene Transfer to the Hybrid Cells using HVJ-E for the Prevention and Treatment of Cancers 611
- 14.4 Biocompatible Polymer with HVJ-E 613
- 14.5 Magnetic Nanoparticles for Medicine 615
- 14.6 Conclusion 620
- References 620
  
- 15 Nanotoxicology of Synthetic Gene Transfer Vectors: Poly(ethyleneimine)- and Polyfectin-mediated Membrane Damage and Apoptosis in Human Cell Lines 629**  
*Seyed M. Moghimi*
- 15.1 Introduction 629
- 15.2 PEI as a Nonviral Vector 630
  - 15.2.1 Structure and Properties of PEI and PEI–DNA Complexes 630
  - 15.2.2 Cytotoxicity 630
- 15.3 PEI-mediated Cell Dysfunction and Apoptosis 631
  - 15.3.1 PEI and PEI–DNA Complex Internalization 631
  - 15.3.2 Plasma Membrane Damage and Apoptosis 632
  - 15.3.3 Effect of PEI on the Function of Isolated Mitochondria 634
  - 15.3.4 Other Plausible Apoptotic Routes 637
- 15.4 Cell Damage and Apoptosis with Related Polycations and Cationic Lipids 638
- 15.5 Conclusions and Future Outlook 639
- References 640
  
- 16 Nanoparticles for the Treatment of Alzheimer’s Disease: Theoretical Rationale, Present Status and Future Perspectives 644**  
*Gang Liu, Ping Men, George Perry and Mark A. Smith*
- 16.1 Introduction 644
- 16.2 Rationales: The Ability of Nanoparticles to Cross the BBB – A Useful Tool to Deliver Drugs into the Brain 645
  - 16.2.1 Physiological Functions of the BBB 645
  - 16.2.2 Strategies for Drug BBB Penetration 646
  - 16.2.3 Preparation of Polymeric Nanoparticulate Drug Delivery Systems 648
  - 16.2.4 Possible Mechanisms by which Nanoparticles Cross the BBB 650
- 16.3 Status: Nanoparticle Targeting Transport of Therapeutic Agents for Potential Treatment of AD 652
  - 16.3.1 Nanoparticle Targeting of A $\beta$  to Deliver Potentially Therapeutic Agents 652
  - 16.3.2 Nanoparticulate Antioxidant Delivery to Increase Efficacy against A $\beta$ -mediated Oxidative Stress 653

16.3.3	Nanoparticle Delivery of Copper Chelator for Preventing and Reversing $A\beta$ Deposition	657
16.3.4	Nanoparticle Transport of Iron Chelators and Metal Chelator Complexes Into and Out of the Brain, Respectively	661
16.3.4.1	Increased Levels of Various Metals in the Brain of AD Patients	661
16.3.4.2	Problems with Iron Chelators for Simultaneous Removal of Multimetal Ions for Treatment of AD	662
16.3.4.3	Nanoparticle Transport Technology to Improve Chelation Therapy for AD	665
16.3.4.4	Experimental Descriptions	666
16.3.4.5	Results and Discussion	676
16.4	Perspectives	683
	Acknowledgments	685
	References	685